Cooley M&A

JULY 10, 2017

In life sciences/medical technology transactions, buyers and sellers often use milestone-based and sometimes royalty-based contingent consideration to compensate sellers for assets that are in various stages of development from clinical- to development-stage to product commercialization. [1] Private placement. Subsequent transfer.

Securities 52

Securities IT Investors M&A 52

Lake Country Advisors

MARCH 22, 2024

A straightforward negotiation style considered the norm for a Wisconsin-based manufacturing firm might seem overly aggressive to executives from a company with a more indirect communication approach. Implications for Your Industry: Understanding cultural decision-making preferences will streamline sales processes.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Acquisitions Healthcare 52

Software Equity Group

MARCH 26, 2024

Among its six SaaS buys over the past year, the firm made several strategic investments in the healthcare space, including the Netherlands-based medical data analytics firm Logex Group, BlueSight, an inventory management system developer for hospitals, and NextGen Healthcare.

Private Equity 52

Private Equity Equities Investment Portfolio 52

Focus Investment Banking

MARCH 28, 2024

Waiting to Recapitalize We expect many PPM recapitalizations (the sale of a PPM company from one investor group to another) in 2025, assuming more clarity around interest rates arrives beforehand. First, the effect of interest rates on individual practice sales has been limited. Download the article.

Private Equity 52

Private Equity Equities Valuation Acquisitions 52

Lake Country Advisors

SEPTEMBER 30, 2024

A clear illustration of this is in the healthcare industry, where compliance with HIPAA and medical licensing regulations is non-negotiable. Infringements can lead to costly lawsuits and may require the company to halt the production or sale of infringing products, affecting revenue.

Business 52

Business Valuation Financial Statement Broker 52

Growth Business

OCTOBER 2, 2023

In the last few years, new start-up and growth businesses have begun using AI to develop analytics platforms and planning tools to improve sales performance for smaller retailers. It also serves to professionalise the documentation and appearance of the company when engaging in contract negotiations with customers and suppliers.

Finance 52

Finance Finance Capital Funds 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JUNE 10, 2020

At the most basic level, a buyer wants to understand two things: (1) is there an unmet medical need such that the company’s development-stage product will substantially improve the quality of care, and (2) is there sufficient exclusivity to allow commercialization of the product. Marketing the opportunity and other process considerations.

M&A 40

M&A Medical Acquisitions Business 40

Cooley M&A

JANUARY 25, 2024

billion sale to Amgen; however, the parties eventually settled the matter on the eve of trial. Acquirers must be prepared for potential litigation domestically and internationally, and for more detailed negotiations over regulatory and interim operating covenants.

M&A 52

M&A Mergers and Acquisitions Investment Government 52

Cleary M&A and Corporate Governance Watch

MARCH 29, 2023

However, we expect that there will be lots of negotiating over the fiscal 2024 budget, so one or more of these proposals may find their way into the final budget. Under these policies, the amount paid is not based on the amount of any medical expense incurred, nor are payments coordinated with other health care coverage.

Accountant 52

Accountant Medical Investment Funds 52

Cooley M&A

JANUARY 25, 2023

Despite the mixed success of these campaigns, their prevalence has led public company boards to focus on activist preparedness –particularly as private equity sponsors increasingly team up with, or quickly follow, activists advocating for a sale.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. billion strategic combination of One Medical and Iora Health – used all stock. [9] closing friction. billion (including earnouts).

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Lake Country Advisors

FEBRUARY 14, 2025

This expertise ensures that industry-specific nuances are accounted for, which can significantly impact the sale outcome. Understanding the Role of Industry Expertise in Business Brokerage Industry expertise is a decisive factor in the success of a business sale.

Broker 52

Broker Business Valuation Healthcare 52

Lake Country Advisors

JANUARY 13, 2025

This data-driven approach provides a comprehensive valuation, ensuring realistic expectations and a stronger position during negotiations with buyers. Identify Prospective Buyers Finding the right buyer is essential for a successful sale. Initiate the Purchase Proposal Process The proposal phase sets the tone for negotiations.

Broker 52

Broker M&A Business Negotiation 52

Focus Investment Banking

MARCH 7, 2025

Again, this illustrates the importance of seeking multiple offers and negotiating each before choosing a winner. Rollover Equity Selling shareholders often receive rollover equity as a portion of transaction value, especially in medical practice and dental deals.

Healthcare 52

Healthcare Private Equity Equities Professional Services 52

Cooley M&A

JANUARY 22, 2025

By 2030, more than 190 commercial drugs will lose patent exclusivity , putting at risk $236 billion in Big Pharma sales. The sale of Poseida Therapeutics, a cell and gene therapy-focused company, for up to $1.5 billion sale of Carmot Therapeutics, a promising Swiss GLP-1 drug developer, further underscores the sectors vitality.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64

Growth Business

JANUARY 28, 2025

Synergy Vision Ffyona Dawber, CEO of Synergy Vision , talks about why she moved the medical comms business to a four-day model and how the company has done it. I suppose there are extra problems there with resource and a smaller business may not having the cash flow to be able to negotiate that. And the same with retention as well.

Business 52

Business IT Recruitment Government 52

Mergers and Inquisitions

MARCH 19, 2025

Modest CapEx Requirements If you look at Damodarans data on capital intensity by sector , certain verticals were below the average 4 5% Net CapEx / Sales reported by U.S. So, PE firms dont have much room to boost sales, cut costs, or do roll-ups because the industry is already quite concentrated.

Private Equity 59

Private Equity Retail Equities Mergers and Acquisitions 59